|
May 30
|
Qualigen Therapeutics, Inc. Received Nasdaq Notice of a Delisting Determination
|
|
Apr 16
|
Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™
|
|
Apr 10
|
Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting
|
|
Apr 9
|
Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting
|
|
Nov 27
|
QLGN: Dosing Begins in Phase 1 Trial of QN-302…
|
|
Nov 7
|
Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors
|